Analysts forecast that Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) will report earnings of $0.94 per share for the current quarter, Zacks reports. Five analysts have made estimates for Valeant Pharmaceuticals International’s earnings. The lowest EPS estimate is $0.83 and the highest is $1.06. Valeant Pharmaceuticals International reported earnings per share of $1.55 in the same quarter last year, which indicates a negative year-over-year growth rate of 39.4%. The firm is scheduled to announce its next earnings report on Tuesday, November 14th.

On average, analysts expect that Valeant Pharmaceuticals International will report full-year earnings of $3.73 per share for the current fiscal year, with EPS estimates ranging from $3.43 to $4.04. For the next financial year, analysts forecast that the firm will post earnings of $3.64 per share, with EPS estimates ranging from $3.05 to $4.30. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Valeant Pharmaceuticals International.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The company had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. During the same quarter last year, the company earned ($0.88) EPS. The company’s quarterly revenue was down 7.7% on a year-over-year basis.

Several equities analysts have recently commented on the company. J P Morgan Chase & Co set a $10.00 target price on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Monday, July 17th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $23.00 target price on shares of Valeant Pharmaceuticals International in a research report on Tuesday, August 29th. Guggenheim assumed coverage on Valeant Pharmaceuticals International in a research report on Saturday, June 17th. They issued a “buy” rating and a $18.00 target price on the stock. Wells Fargo & Company reaffirmed an “underperform” rating and issued a $9.00 target price on shares of Valeant Pharmaceuticals International in a research report on Thursday, August 10th. Finally, Deutsche Bank AG set a $19.00 target price on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Monday, August 21st. Five equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the stock. Valeant Pharmaceuticals International presently has an average rating of “Hold” and an average target price of $17.62.

ILLEGAL ACTIVITY WARNING: This story was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.watchlistnews.com/brokerages-anticipate-valeant-pharmaceuticals-international-inc-vrx-will-announce-earnings-of-0-94-per-share/1589611.html.

In other news, Director Schutter Richard U. De purchased 10,000 shares of the company’s stock in a transaction dated Monday, August 21st. The stock was bought at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the purchase, the director now owns 77,479 shares of the company’s stock, valued at $1,110,274.07. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 5.87% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Armstrong Henry H Associates Inc. lifted its stake in shares of Valeant Pharmaceuticals International by 0.3% in the 2nd quarter. Armstrong Henry H Associates Inc. now owns 93,753 shares of the specialty pharmaceutical company’s stock valued at $1,622,000 after acquiring an additional 295 shares during the last quarter. World Asset Management Inc raised its position in Valeant Pharmaceuticals International by 1.5% during the 1st quarter. World Asset Management Inc now owns 21,502 shares of the specialty pharmaceutical company’s stock worth $237,000 after purchasing an additional 328 shares during the last quarter. Eaton Vance Management raised its position in Valeant Pharmaceuticals International by 1.2% during the 2nd quarter. Eaton Vance Management now owns 43,469 shares of the specialty pharmaceutical company’s stock worth $752,000 after purchasing an additional 500 shares during the last quarter. IFP Advisors Inc raised its position in Valeant Pharmaceuticals International by 0.4% during the 2nd quarter. IFP Advisors Inc now owns 128,305 shares of the specialty pharmaceutical company’s stock worth $2,220,000 after purchasing an additional 509 shares during the last quarter. Finally, NEXT Financial Group Inc raised its position in Valeant Pharmaceuticals International by 6.2% during the 2nd quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock worth $178,000 after purchasing an additional 600 shares during the last quarter. Institutional investors own 50.47% of the company’s stock.

Shares of Valeant Pharmaceuticals International (NYSE VRX) traded up 0.21% during mid-day trading on Tuesday, hitting $14.12. The company’s stock had a trading volume of 2,656,865 shares. The company has a 50-day moving average of $14.22 and a 200 day moving average of $13.18. The company’s market cap is $4.92 billion. Valeant Pharmaceuticals International has a 1-year low of $8.31 and a 1-year high of $27.84.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get a free copy of the Zacks research report on Valeant Pharmaceuticals International (VRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.